An investigation for investors in NASDAQ:TGTX shares over potential securities laws violations by TG Therapeutics and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of TG Therapeutics Inc (NASDAQ:TGTX), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of TG Therapeutics Inc (NASDAQ:TGTX) concerning whether a series of statements by TG Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
New York based TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. Shares of TG Therapeutics Inc grew from $5.49 per share in August 2016 to as high as $9.33 per share on October 10, 2016.
Then on October 13, 2016, TG Therapeutics Inc that it had filed with the FDA an amended protocol for its leukemia drug combination, GENUINE Phase 3 Trial. In the amendments, the Company eliminated part II of the GENUINE study and reduced the number of randomized patients from 200 to approximately 120. The Company no longer benefits from of its previously negotiated Special Protocol Assessment with the FDA. Shares of TG Therapeutics Inc declined to as low as $5.77 per share on October 20, 2016.
Those who purchased NASDAQ:TGTX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego